Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Kündgen

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|September 14, 2004
Risk assessment in chronic myelomonocytic leukemia (CMML)U Germing, A Kündgen, N Gattermann
Deutsche Medizinische Wochenschrift (1946)|January 27, 2012
[Myelodysplastic syndromes (MDS)]U Germing, A Kündgen, R Haas, et al.
Leukemia Research|June 28, 2005
Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomideC Strupp, R Fenk, A Kündgen, et al.
European Journal of Haematology|February 14, 2004
Thalidomide for the treatment of idiopathic myelofibrosisC Strupp, U Germing, A Scherer, et al.
Annals of Hematology|March 29, 2006
Primary pancreatic lymphoma--a rare cause of cholestasis leading to surgical treatmentI Alldinger, M Peiper, R Diallo, et al.
Leukemia & Lymphoma|July 16, 2005
The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomideC Strupp, U Germing, M Aivado, et al.
Leukemia Research|December 3, 2014
Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemiasE Schuler, M Schroeder, J Neukirchen, et al.
Annals of Hematology|November 18, 2005
Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabineJ A Pitako, P S Haas, J Van den Bosch, et al.
Annals of Hematology|November 7, 2020
Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromesA Kasprzak, K Nachtkamp, M Kondakci, et al.
Leukemia|June 26, 2013
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cellsS Geyh, S Oz, R-P Cadeddu, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|September 14, 2004
Risk assessment in chronic myelomonocytic leukemia (CMML)U Germing, A Kündgen, N Gattermann
Deutsche Medizinische Wochenschrift (1946)|January 27, 2012
[Myelodysplastic syndromes (MDS)]U Germing, A Kündgen, R Haas, et al.
Leukemia Research|June 28, 2005
Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomideC Strupp, R Fenk, A Kündgen, et al.
European Journal of Haematology|February 14, 2004
Thalidomide for the treatment of idiopathic myelofibrosisC Strupp, U Germing, A Scherer, et al.
Annals of Hematology|March 29, 2006
Primary pancreatic lymphoma--a rare cause of cholestasis leading to surgical treatmentI Alldinger, M Peiper, R Diallo, et al.
Leukemia & Lymphoma|July 16, 2005
The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomideC Strupp, U Germing, M Aivado, et al.
Leukemia Research|December 3, 2014
Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemiasE Schuler, M Schroeder, J Neukirchen, et al.
Annals of Hematology|November 18, 2005
Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabineJ A Pitako, P S Haas, J Van den Bosch, et al.
Annals of Hematology|November 7, 2020
Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromesA Kasprzak, K Nachtkamp, M Kondakci, et al.
Leukemia|June 26, 2013
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cellsS Geyh, S Oz, R-P Cadeddu, et al.
Pageof 3